11/17
09:12 am
srdx
Surmodics gains as FTC won't appeal denial of GTCR deal injunction [Seeking Alpha]
Low
Report
Surmodics gains as FTC won't appeal denial of GTCR deal injunction [Seeking Alpha]
11/17
06:13 am
srdx
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today [Yahoo! Finance]
Low
Report
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today [Yahoo! Finance]
11/17
06:00 am
srdx
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
Low
Report
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
11/14
11:47 am
srdx
Surmodics (NASDAQ:SRDX) was downgraded by analysts at Barrington Research from a "market perform" rating to an "underperform" rating.
Low
Report
Surmodics (NASDAQ:SRDX) was downgraded by analysts at Barrington Research from a "market perform" rating to an "underperform" rating.
11/13
06:26 pm
srdx
Judge denies FTC's bid to block $627M Surmodics buyout [Yahoo! Finance]
Low
Report
Judge denies FTC's bid to block $627M Surmodics buyout [Yahoo! Finance]
11/10
07:46 pm
srdx
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR [Yahoo! Finance]
High
Report
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR [Yahoo! Finance]
11/10
07:00 pm
srdx
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
High
Report
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
11/10
04:45 pm
srdx
Surmodics sale to GTCR approved by federal court [Seeking Alpha]
High
Report
Surmodics sale to GTCR approved by federal court [Seeking Alpha]
11/4
06:15 am
srdx
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Low
Report
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
11/3
06:15 am
srdx
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
Medium
Report
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
10/29
04:15 pm
srdx
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
Low
Report
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
10/27
04:05 pm
srdx
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28
Low
Report
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28
10/3
03:45 pm
srdx
Surmodics (NASDAQ:SRDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Surmodics (NASDAQ:SRDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.